292 related articles for article (PubMed ID: 27502705)
1. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
Novotny JF; Cogswell J; Inzunza H; Harbison C; Horak C; Averbuch S
Ann Oncol; 2016 Oct; 27(10):1966-9. PubMed ID: 27502705
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
Galsky MD
Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
[No Abstract] [Full Text] [Related]
4. Nivolumab for treating non-small cell lung cancer.
Guibert N; Mazières J
Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
[TBL] [Abstract][Full Text] [Related]
5. Do immune-related adverse events correlate with response to immune checkpoint inhibitors?
Saleh K; Khalife-Saleh N; Kourie HR
Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551
[No Abstract] [Full Text] [Related]
6. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death protein receptor and ligands in haematological malignancies - Current status.
Sokołowski M; Sokołowska A; Mazur G; Butrym A
Crit Rev Oncol Hematol; 2019 Mar; 135():47-58. PubMed ID: 30819446
[TBL] [Abstract][Full Text] [Related]
8. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
9. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
10. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
[TBL] [Abstract][Full Text] [Related]
11. Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?
Saleh K; Khalifeh-Saleh N; Kourie HR; Nasr F; Chahine G
Immunotherapy; 2018 Mar; 10(3):163-165. PubMed ID: 29370724
[No Abstract] [Full Text] [Related]
12. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
[TBL] [Abstract][Full Text] [Related]
14. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
Wu Y; Lin L; Shen Y; Wu H
Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
[No Abstract] [Full Text] [Related]
15. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
16. "Dangling" Accelerated Approvals in Oncology.
Beaver JA; Pazdur R
N Engl J Med; 2021 May; 384(18):e68. PubMed ID: 33882220
[No Abstract] [Full Text] [Related]
17. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
18. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Zahavi DJ; Weiner LM
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
[TBL] [Abstract][Full Text] [Related]
19. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
Upadhaya S; Neftelino ST; Hodge JP; Oliva C; Campbell JR; Yu JX
Nat Rev Drug Discov; 2021 Mar; 20(3):168-169. PubMed ID: 33177720
[No Abstract] [Full Text] [Related]
20. Are virus-induced cancers more sensitive to checkpoint inhibitors?
Kanaan H; Kourie HR; Awada AH
Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
